-
Something wrong with this record ?
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
D. Žáčková, L. Semerád, E. Faber, H. Klamová, L. Stejskal, P. Bělohlávková, M. Karas, E. Cmunt, O. Černá, J. Procházková, P. Čičátková, A. Kvetková, T. Horňák, I. Skoumalová, D. Srbová, C. Šálek, D. Buffa, J. Voglová, T. Jurček, A. Folta, I....
Language English Country England, Great Britain
Document type Journal Article
Grant support
NU22-03-00136
Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic)
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
- MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive * drug therapy MeSH
- Chronic Disease MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Tyrosine Kinase Inhibitors MeSH
- Humans MeSH
- Leukemia, Myeloid * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
1st Dpt of Internal Medicine Hematology General University Hospital Prague Czech Republic
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic
Dpt of Hemato oncology University Hospital Olomouc and Palacký University Olomouc Czech Republic
Dpt of Hemato oncology University Hospital Ostrava and Ostrava University Ostrava Czech Republic
Dpt of Hemato oncology University Hospital Plzeň and Charles University Plzeň Czech Republic
Institute of Hematology and Blood Transfusion Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014446
- 003
- CZ-PrNML
- 005
- 20240905133511.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-024-02215-9 $2 doi
- 035 __
- $a (PubMed)38472478
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Žáčková, Daniela $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic. Zackova.daniela@fnbrno.cz $1 https://orcid.org/0000000198028148 $7 xx0074334
- 245 10
- $a Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF / $c D. Žáčková, L. Semerád, E. Faber, H. Klamová, L. Stejskal, P. Bělohlávková, M. Karas, E. Cmunt, O. Černá, J. Procházková, P. Čičátková, A. Kvetková, T. Horňák, I. Skoumalová, D. Srbová, C. Šálek, D. Buffa, J. Voglová, T. Jurček, A. Folta, I. Ježíšková, H. Žižková, K. Machová Poláková, T. Papajík, P. Žák, P. Jindra, A. Svobodník, R. Štěpánová, J. Mayer
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibitory tyrosinkinasy $7 D000092004
- 650 12
- $a chronická myeloidní leukemie $x farmakoterapie $7 D015464
- 650 12
- $a myeloidní leukemie $7 D007951
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Semerád, Lukáš $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Faber, Edgar $u Dpt. of Hemato-oncology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Klamová, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Stejskal, Lukáš $u Dpt. of Hemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic
- 700 1_
- $a Bělohlávková, Petra $u 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Karas, Michal $u Dpt. of Hemato-oncology, University Hospital Plzeň and Charles University, Plzeň, Czech Republic
- 700 1_
- $a Cmunt, Eduard $u 1st Dpt. of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic
- 700 1_
- $a Černá, Olga $u Dpt. Of Hematology, University Hospital Královské Vinohrady and Charles University, Prague, Czech Republic
- 700 1_
- $a Procházková, Jiřina $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Čičátková, Petra $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Kvetková, Anežka $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Horňák, Tomáš $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000270033372
- 700 1_
- $a Skoumalová, Ivana $u Dpt. of Hemato-oncology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Srbová, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Šálek, Cyril $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000200213247 $7 xx0098743
- 700 1_
- $a Buffa, David $u Dpt. of Hemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic
- 700 1_
- $a Voglová, Jaroslava $u 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Jurček, Tomáš $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Folta, Adam $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Ježíšková, Ivana $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Žižková, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Machová Poláková, Kateřina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Papajík, Tomáš $u Dpt. of Hemato-oncology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Žák, Pavel $u 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Jindra, Pavel $u Dpt. of Hemato-oncology, University Hospital Plzeň and Charles University, Plzeň, Czech Republic $1 https://orcid.org/0000000284157069 $7 xx0098857
- 700 1_
- $a Svobodník, Adam $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Štěpánová, Radka $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Mayer, Jiří $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC) Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000305679887 $7 nlk20000083651
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 38, č. 4 (2024), s. 893-897
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38472478 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133505 $b ABA008
- 999 __
- $a ok $b bmc $g 2143917 $s 1226312
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 4 $d 893-897 $e 20240312 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- GRA __
- $a NU22-03-00136 $p Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic)
- LZP __
- $a Pubmed-20240725
